Revolution Medicines' drug nearly doubles survival in pancreatic cancer trial

Revolution Medicines reported that its drug daraxonrasib raised median overall survival to 13.2 months from 6.7 months versus chemotherapy in a late-stage trial, and the company plans to submit the trial data to the U.S. Food and Drug Administration and other global regulators.

Revolution Medicines reported that its oral drug daraxonrasib increased median overall survival for people with metastatic pancreatic cancer in a late-stage trial. Median overall survival was 13.2 months with the experimental treatment versus 6.7 months with chemotherapy, and the company reported the difference as statistically significant. The company said it plans to submit the trial data to the US Food and Drug Administration and other global regulators for potential approval. Key facts: - The late-stage trial showed median overall survival of 13.2 months for daraxonrasib versus 6.7 months for chemotherapy. - The company announced the survival difference was statistically significant. - The medicine is an oral drug described as targeting mutated RAS genes and is named daraxonrasib. - Revolution Medicines said it will submit the trial data to the FDA and other global regulatory authorities; the drug was previously selected for an FDA voucher program. Summary: The trial result shows a reported substantial increase in median overall survival for the study group. The company has stated its next step is to submit the data to regulatory authorities, after which formal regulatory review and decisions will follow.